SLC6A3 and Parkinson disease: Patients with LRRK2 G2019S showed a similar trajectory of DAT decline to the sPD group, whereas GBA PD patients exhibited a rapid decrease in DAT availability during the premotor phase compared to sPD or a subset with the LRRK2 mutation.